Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral AgentRaju Subramanian, Bill J. Smith, Scott A. Wolckenhauer et al.|Molecular Pharmaceutics|2023Cited by 52
Pharmacokinetics, Disposition, and Biotransformation of [14C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous InfusionElijah Weber, Renu Singh, Raju Subramanian et al.|Clinical Pharmacokinetics|2024Cited by 17
539. GS-CA2: A Novel, Potent, and Selective First-In-class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in HumansJim Zheng, Winston C. Tse, Stephen R. Yant et al.|Open Forum Infectious Diseases|2018Cited by 15
Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance PathwayJim Zheng, Raju Subramanian, Bing Lu et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 13
Discovery ofLenacapavir: First-in-Class Twice-YearlyCapsid Inhibitor for HIV-1 Treatment and Pre-exposure ProphylaxisEda Canales, John O. Link, Winston C. Tse et al.|Journal of Medicinal Chemistry|2025Cited by 11